VTVT
vTv Therapeutics Inc - Ordinary Shares - Class A

14,780
Mkt Cap
$134.73M
Volume
11,786.00
52W High
$33.16
52W Low
$13.15
PE Ratio
-9.70
VTVT Fundamentals
Price
$31.53
Prev Close
$32.24
Open
$32.24
50D MA
$23.42
Beta
0.83
Avg. Volume
4,133.52
EPS (Annual)
-$3.20
P/B
1.80
Rev/Employee
$44,217.39
Loading...
Loading...
News
all
press releases
All You Need to Know About vTv Therapeutics (VTVT) Rating Upgrade to Buy
vTv Therapeutics (VTVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·9d ago
News Placeholder
More News
News Placeholder
Q1 Earnings Estimate for VTVT Issued By HC Wainwright
vTv Therapeutics Inc. (NASDAQ:VTVT - Free Report) - Stock analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for vTv Therapeutics in a research note issued to investors on...
MarketBeat·11d ago
News Placeholder
vTv Therapeutics (NASDAQ:VTVT) Releases Earnings Results, Misses Estimates By $0.11 EPS
vTv Therapeutics (NASDAQ:VTVT - Get Free Report) announced its quarterly earnings results on Thursday. The biotechnology company reported ($1.08) earnings per share for the quarter, missing the...
MarketBeat·13d ago
News Placeholder
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR...
PR Newswire·1y ago
News Placeholder
CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING
CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON...
PR Newswire·1y ago
News Placeholder
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF PANCREATIC CANCER
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF PANCREATIC CANCER CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE...
PR Newswire·2y ago
News Placeholder
vTv Therapeutics Inc. (NASDAQ:VTVT) Sees Large Growth in Short Interest
vTv Therapeutics Inc. (NASDAQ:VTVT Get Free Report) saw a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 57,200 shares, a growth...
Zolmax·2y ago
News Placeholder
CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT
CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT PR Newswire WESTON, Fla...
PR Newswire·2y ago
News Placeholder
vTv Therapeutics expects cash to fund operations through Phase 3 study data
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
Recently completed $51 million PIPE from healthcare-focused institutional investors and the JDRF T1D Fund.Company's first Phase 3 clinical trial of cadisegliatin (TTP399), an oral adjunctive therapy...
Globe Newswire·2y ago

Latest VTVT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.